25 th Annual ROTH Conference NYSE MKT: BTX

25th AnnualROTH ConferenceNYSE MKT: BTX March, 2013

Forward Looking Statements The matters discussed in this presentation include forward looking statements which are subject to various risks, uncertainties, and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not limited to the success of BioTime in developing new stem cell products and technologies; results of clinical trials of BioTime products; the ability of BioTime and its licensees to obtain additional FDA and foreign regulatory approval to market BioTime products; competition from products manufactured and sold or being developed by other companies; the price of and demand for BioTime products; and the ability of BioTime to raise the capital needed to finance its current and planned operations. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. As actual results may differ materially from the results anticipated in these forward-looking statements they should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

The Health Care Challenge & Opportunity • A global tsunami of health care costs from ineffectiveness of drugs to treat chronic degenerative disease (CDD) • CDD due to lack of cellular regeneration • 80% Americans have CDD of aging • 50% of Americans have two CDDs • 95% costs in aging is CDD

The Health Care Challenge & Opportunity • Progressive evolution of new & more interventional products over past four decades Recombinant DNA Technology • Regenerative Medicine Monoclonal Antibodies • 1998 – Embryonic Stem Cells allowing for the first time in the history of medicine the manufacture of all human cellular components • 2001 – U.S. Federal funding restriction (reversed in 2009) • 2010 – 1sthES Clinical trial • Future – 1st $B product • 1975 - Hybridoma technology developed • 1997- First $B Product Rituximab • Advances in Mab Engineering • Today, eight of the 20 best-selling biotechnology drugs in therapeutic monoclonal antibodies • > 200 clinical trials • Current Global Market $44 B • 1974 – Gene cloning technology developed • 1976 - Moratorium on rDNA research initiated led to established guidelines on rDNA research • 1989 – First $B product EPO • Today, products from the use of rDNA technology are ubiquitous • >140 clinical trials • Current Global Market $75 B

The BioTime Opportunity • Consolidating key stem cell assets • - ES Cell International • - Geron stem cell assets • - HyStem hydrogels • Integration with PureStem technology • Focus on near-term products • Significant clinical milestones for 2013

PureStem Manufacturing Technology • Human embryonic progenitor (hEP) • cell lines: > 200 diverse cell types isolated • Diversity • Precise identity • Purity • Scalability • Patents pending Kidney Smooth Muscle Skeletal Muscle Blood/Brain Barrier

ReneviaTM – Cell Delivery Device • Injectable, biocompatible, and biodegradable Low COGs, Stable Product, Potential Widespread Applications Cells in Renevia Matrix (Cross-linked Collagen and Hyaluronate)

HyStem Hydrogels – Competitive Advantages Injectable Stays as liquid for ~ 20 minutes Polymerizes safely in vivo Supports survival of cells and 3-D structure Multiple Formulations Heparin-mediated Slow Release Cast Hydrogel Cells in Sponge 3-D Lattices Durable Films

ReneviaTM – Development • Indication: As a delivery matrix for autologous adipose derived cells to correct subcutaneous lipoatrophy arising from trauma, oncologic resection, or congenital defect. • 3 Phase Clinical Evaluation ofReneviaTM • • Phase 1: Safety - open label, ReneviaTM only, subcutaneous injection, 10 subjects, 4 week follow up. • • Phase 2: Treatment Effect - open label, ReneviaTM+ ADSCs, 15 patients, 3-6 months follow up. • • Phase 3: Pivotal - randomized, controlled, evaluator blind, non-inferiority, ReneviaTM+ ADSCs vs. Cell-Assisted Lipotransfer, # of patient per group TBD, 6 months follow up. • • Primary endpoints: Aesthetic Improvement Score & photo review • • Secondary endpoint:Change in subcutaneous defect volume • • Single Site: The Stem Center, Palma de Mallorca, Spain

ReneviaTM – A Cell Delivery Device • Adipose tissue restoration with autologousASCs • Medical device (CE Mark in the EU then CBER/CDRH) • Outsource cGMP manufacture • Near-term opportunity, low cost for approval ReneviaTMRegulatory Strategy • Expected ReneviaTMCE Mark in 2015 ReneviaTMTimeline Treatment Effect Clinical Trial Initiated Complete cGMP Manufacture CE Mark Renevia™ Final Dossier Submission Safety Clinical Trial Initiated Pivotal Clinical Trial Initiated ISO 13485 Certification Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2012 2013 2014 2015

Potential ReneviaTM Applications Potential Applicable U.S. Market Potential Utility • Heart Disease ✔165 B • Alzheimer’s ✔ 69 B • Diabetes ✔ 92 B • Stroke ✔ 28 B • Renal Failure ✔ 33 B Regen. Med. (2008) 3(3), 351–363

OncoCyte Corporation Cancer diagnostics and anti-cancer therapies • Cell Cure Neurosciences Ltd. Age-related macular degeneration (AMD) Subsidiaries • OrthoCyte Corporation Cartilage repair • ReCyte Therapeutics, Inc. Age-related vascular disorders • ES Cell International PTE Ltd. Clinical-grade master stem cell banks • LifeMap Sciences, Inc. Stem cell data base and research products • BioTime Acquisition Corp.. • Expected Contribution of Geron and BioTime Assets

OncoCyte Corporation- PanC-DxTM • Screening in asymptomatic patients is the largest market opportunity PanC-DxTM • Pan diagnostic to detect the presence of various human cancers, including cancers of the breast, lung, bladder, uterus, stomach, and colon, during routine check-ups using a low-cost antibody-based blood test. • mAb production for seven antigens in process • Specificity of >50 mAbscharacterized • Dynamic testing for use in ELISA and point of care formats currently underway. • Initially develop and seek regulatory approval of PanC-DxTMin Europe • Expected launch in 2014

PanC-DxTM Cancer Diagnostic • CE Mark (EU) then CDRH/OIVD (U.S.) • Near-term opportunity, low cost for approval Regulatory Strategy Timeline leading to 2014 launch Antibody Screening Marker Validation Final Kit Developed CE Mark Antibody Production Patient Study Completion Q4 Q3 Q3 Q3 Q3 Q1 Q2 Q1 Q2 Q1 Q2 Q4 Q4 Q4 2013 2011 2012 2014

Cell Cure Neurosciences Ltd. • OpRegen® – RPE Cells for the Treatment of AMD • 7.3 million have early stage dry AMD in US • Any effective treatment expected to achieve blockbuster sales • OpRegen® – Suspension of retinal pigment epithelial (RPE) cells for dry age-related macular degeneration (AMD) • OpRegen® Plus – Matrix bound RPE cells for dry AMD • Partnered with TEVA

Cell Cure Neurosciences Ltd. • Planned IND in 2013/2014 • Phase I/IIa Study of hESC-RPE in Progressive Dry-Form Age-Related Macular Degeneration (12 patients, 1 year follow up time, single doses) • Primary endpoint: Safety • Secondary endpoint: Efficacy • • Visual Acuity • • Maintenance of graft size over serial measurements (graft survival) • • Reduced expansion of geographic atrophy in grafted sites vs. non- • grafted sites (in the same eye) • • Perimetry- extent and depth of central scotomata • • Single site: Hadassah, Israel • Duration (enrollment and follow up): 18 months

OrthoCyte Corporation • Developing regenerative therapeutics for orthopedic applications • Cartilage cannot regenerate on its own • Osteoarthritis and spinal disc degeneration have a significant impact on mobility and health • > 26 million people in U.S. and growing • Drug treatments target the reduction of pain and inflammation as opposed to repairing tissue • Studies in animal models of IVD disease underway • Non-hypertrophic progenitors • Off the shelf approach

OrthoCyte- Cartilage Progenitors E15

Regenerative Medicine Human embryonic stem (hES) for limited allogeneic applications Twin strategies for cell transplantation • Sites behind the blood brain barrier • Sites behind synovial membranes • Cells targeting tumors for destruction Human induced pluripotent stem (iPS) cells for auto-logous transplantation • Vascular disease

ReCyte Therapeutics, Inc. RCX-VP01 for Age-Related Vascular Insufficiency • American Heart Association Report on Heart Disease and Stroke Statistics: • 2011 Update • Cardiovascular Disease (CVD) • Prevalence: •  82,600,000 American adults (>1 in 3) with 1 or more types of CVD •  2200 deaths from CVD per day; average life expectancy shortened 7 years • Stroke (Cerebrovascular Disease) • Incidence: •  800,000 new (77%) or recurrent (23%) strokes per year •  1 of every 18 deaths in U.S. in 2007 • Healthcare Impact and Cost: •  $286 billion total direct and indirect costs of CVD and stroke in U.S. in 2007 • nearly 7 million inpatient cardiovascular operations and procedures in 2007

OncoCyte Corporation Cancer diagnostics and anti-cancer therapies • Cell Cure Neurosciences Ltd. Age-related macular degeneration (AMD) Subsidiaries • OrthoCyte Corporation Cartilage repair • ReCyte Therapeutics, Inc. Age-related vascular disorders • ES Cell International PTE Ltd. Clinical-grade master stem cell banks • LifeMap Sciences, Inc. Stem cell data base and research products • BioTime Acquisition Corp.. • Expected Contribution of Geronand BioTime Assets

LifeMap Sciences, Inc. The leading human gene database • • Used in more than 1,000 institutions world-wide including academia, research hospitals, patent offices, and the leading biotech and pharma • • More than 12 Million page visits/year by hundreds of thousands of unique users • • 30% usage growth in the past 12 months • • Consistently leads in top positions for gene search results in Google

LifeMapBioReagents • >12 Million page hits/yr • BioTime Products • Third Party Products Cells > 1,000 USCN Antibody kits >1,000 Prospec- TanyTechnogene Proteins Diseases Genes • Near-term Revenue • Seed for Future Royalties • All online • % of Sales • Powerful Marketing Platform

OncoCyte Corporation Cancer diagnostics and anti-cancer therapies • Cell Cure Neurosciences Ltd. Age-related macular degeneration (AMD) Subsidiaries • OrthoCyte Corporation Cartilage repair • ReCyte Therapeutics, Inc. Age-related vascular disorders • ES Cell International PTE Ltd. Clinical-grade master stem cell banks • LifeMap Sciences, Inc. Stem cell data base and research products • BioTime Acquisition Corp.. Contribution of Geron and BioTime Assets

BioTime Acquisition Corp. • What Geron Contributes and Receives… Terms subject to closing • Geron will contribute: • IP and tangible assets related to hES programs • Phase 1 trials in acute spinal cord injury & T’ase vaccine • IP and sublicense to autologous cellular immunotherapy program • Interests in non-therapeutic applications • including products developed and sold by GE Heathcare • Geron receives: • Shares in BAC (approx 21.4% interest) • Royalties on sale of products using Geron patents • Shares will be distributed by Geron to their shareholders • (following closing)

BioTime Acquisition Corp. • What BioTime Contributes and Receives… Terms subject to closing • BioTime will contribute to BAC: • $5 million in cash (committed through a private investor) • 8.9 MM in BioTime Common Stock to be held by BAC • 8 million BioTime warrants • At closing, to be distributed by BAC to Geron stockholders • Minority equity interest in OrthoCyte and Cell Cure • Rights to use certain BioTime cell lines • BioTime receives: • Shares in BAC (Approx. 71.6% interest in BAC) • 3.15 MM Warrants in BAC

BioTime Acquisition Corp. • Stem Cell Assets Being Contributed from Geron

BioTime Acquisition Corp. • Stem Cell Assets Being Contributed from Geron >400 issued & pending patent applications worldwide including: • Feeder-free culture of hPS cells • hES-derived dendritic cells for treating cancer • TGFbeta inhibitors & Neural • RNA isolation from hPS cells or derivatives • Feeder free hPS cells in drug screening • Medium for hPS cell culture • hPS-derived hepatocytes • Dopaminergic neurons from hPS cells • hPS cell-specific genetic toxicity • Selective antigen expression on hPS cells

Current Product Pipeline Preclinical Phase I Phase II Phase III Market Partner Hextend Research Products/Database HyStem®Hydrogel Products 2014-2015 Renevia 2014 PanC-DxTM Teva 2013 OpRegen OTX-CP07 RCX-VP01

BioTime (NYSE MKT: BTX) A Technological Leader with Revenue, Low Burn Rate and Near-term Product Opportunities • $4.4MM cash of 12/31/12 • Raised additional $16.3 million to date in 2013 • Approx. $10MM in investments held by our subsidiaries Key Statistics: • Revenue of $3.9MM in 2012 • Avg. qtrly burn rate of $4.9MM per quarter • No debt • Market Cap approx. $240MM as of 3/15/13 Major Shareholders: 17.5% 16.1% 9.2% 46.7% Greenbelt/Greenway/ Al Kingsley (Chairman) Individual Investor Insiders & LT Investors Broadwood Capital (Neal Bradsher, Director) BioTime shareholder base with significant long term investors

BioTime’s Key Milestones • Next 12 months… • Initiation ofHyStem ® -Rxclinical trial • IND filing of OpRegen for AMD • PanC-Dx patient study • Corporate partnering and collaborations • Increased revenue from LifeMapBioReagents

Summary • >200 purified human cell types manufactured for the first time • Leading patent position • Emphasis on near-term products: - ReneviaTM - PanC-DxTM - LifeMapBioReagents • Longer–term first-in-class stem cell-based therapeutics for currently incurable degenerative diseases • Subsidiaries focused on specific disease areas Positioned to Lead the Commercialization of Pluripotency in Regenerative Medicine Alameda, California Headquarters

Thank You Michael West, Ph.D. CEO Pete Garcia CFO 510-521-3390 pgarcia@biotimemail.com

25 th Annual ROTH Conference NYSE MKT: BTX